- Our LinkedIn Page
- Our Twitter Feed
- Our Facebook Page
- Newsletter Subscribe to our e-newsletter. Current Issue
- Our Flickr Feed
- Our YouTube Feed
Authors
- Abigail Hirsch
- Alan Eisenberg
- BIOtechNOW Editor
- Bruce Dale
- Celia Economides
- Colleen Lerro
- David Thomas, CFA
- George Goodno
- George MacDougall
- Jason Corum
- Jeff Joseph
- Jim Greenwood
- Karen Batra
- Kelly Cappio
- Lila Feisee
- Matt Carr
- Nathan Schock
- Paul Winters
- Paulina Ibarra
- Robbi Lycett
- Roy Zwahlen
- Sarah Sneeringer
- Sondra Behan
- Stephanie Fischer
- Stephen Marmaras
- Tracy Cooley
Tag Archives: BIO Investor Forum
Forbes on Flu
Forbes’ Jonathan Fahey wrote an excellent article on influenza and the H1N1 virus this morning. The article is significant for a couple reasons. First, he captures the overall situation so just in case you haven’t read a story or heard about H1N1 yet (and have been living under a rock), you get the full picture quickly and succinctly. Even if you have read about it, it’s always nice to get a quick recap just to Read More >
Trubion Collaboration with Facet Biotech
Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) and Facet Biotech Corporation (Nasdaq: FACT) recently announced an agreement for the joint development and commercialization of TRU-016, a product candidate in phase 1 clinical development for chronic lymphocytic leukemia. TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP(TM)) protein therapeutic. The collaboration agreement includes TRU-016 in all indications and all other CD37-directed protein therapeutics.
Complete Genomics Sequences 14 Human Genomes
Complete Genomics Inc. announced that 14 human genomes now have been sequenced, analyzed and delivered to customers since March 2009. The company’s human genome sequencing technology helps to further research for cancer, metabolic and neurological diseases. Customers include academic research institutions and biopharmaceutical companies that are conducting disease studies to investigate conditions as diverse as cancer (breast, lung, colorectal and melanoma), HIV and schizophrenia. Complete Genomics Inc. will be presenting at the 8th Annual BIO Read More >
Race to Develop H1N1 Vaccine
Execs from Inovio Biomedical Corporation and Novavax will be speaking at BIF about their experience in the race to develop a vaccine for H1N1. Below are a couple recent developments from these companies: Novavax Inc (NVAX.O) recently reported that its seasonal flu vaccine candidate, which uses virus-like particles, induced an immune response against H3N2, H1N1 and B and was well-tolerated in a mid-stage trial. Read the release. Inovio Biomedical Corp. (INO) said it will team up Read More >
PTC Therapeutics Announces Collaboration with Roche
PTC Therapeutics, Inc. announced a research collaboration and licensing agreement with Roche for development of orally bioavailable small molecules using PTC’s technology, Gene Expression Modulation by Small-molecules (GEMS™). As part of the collaboration, Roche is paying PTC Therapeutics $12 million as part of an agreement to develop small molecule CNS disease drugs. Subject to meeting milestones, there is the potential for PTC to earn up to $239 million in research, development, regulatory and commercial milestone Read More >
